Tarek Mekhail, MD, and Mark Socinski, MD: IMforte Trial Efficacy and Safety Outcomes

Drs. Mekhail and Socinski discuss the role of atezolizumab in the treatment of extensive-stage small-cell lung cancer (SCLC), highlighting outcomes from the phase 3 IMforte trial, which evaluated atezolizumab monotherapy vs atezolizumab plus lurbinectedin (IMforte regimen) as maintenance treatment. They review the survival benefits associated with the IMforte regimen; they also highlight the safety outcomes from the IMforte trial.